Radence Review: Can a $13B Hedge Fund Build the Future of Preventive Medicine?
A concierge science startup backed by RA Capital wants to catch your cancer before you know you have it — and charge $50,000 a year for the privilege.
What Is Radence?
A quick note on spelling before we begin: the company is Radence — not “Radiance.” Easy to confuse, impossible to Google correctly on the first try. Consider this your orienteering gift.
Radence is a precision medicine startup that launched its concierge membership service in October 2025. It was incubated inside RA Ventures, the healthcare arm of RA Capital Management, a Boston-based biopharma-focused hedge fund managing roughly $13 billion in assets. That pedigree is not incidental to the pitch — it’s the whole pitch. The company’s value proposition rests substantially on the argument that a fund that has spent decades evaluating drug pipelines, clinical trial data, and diagnostic technologies has a uniquely rigorous perspective on what actually works in preventive medicine.
The company’s clinical team includes more than 50 physicians and researchers with appointments at institutions like Mount Sinai, Brigham and Women’s Hospital, Harvard Medical School, and Weill Cornell Medicine. Its internal think tank, TechAtlas, continuously maps emerging scientific and clinical data from around the world to inform which technologies are worth deploying — and which are hype.
Radence prefers the term “concierge science” to distance itself from the wellness-adjacent longevity clinic space, which it views — charitably — as noisy. The distinction is substantive: rather than selling you a branded supplement stack and a DEXA scan, Radence is positioning itself as a scientific partner to both the member and their existing physician.
The Model: Asset-Light and Deliberately So
One of the more structurally interesting things about Radence is what it doesn’t own. Unlike Fountain Life, which operates proprietary clinical facilities in Dallas, Houston, Miami, Orlando, and White Plains, NY, or Human Longevity, which built out its own scanning infrastructure, Radence operates through a distributed network of partner laboratories and imaging centers. There are no company-owned magnetic resonance imaging (MRI) machines. No branded scanning suites. No fleet of centrifuges with the Radence logo on them.
This is a deliberate strategic choice, and the reasoning behind it is worth understanding. As CEO David Medvedeff explained to Fierce Healthcare: once a company purchases its own scanners, it’s in the utilization business. Owning a $3 million MRI machine creates an institutional incentive to run members through it — whether or not that’s the most clinically appropriate next step. Radence argues that the asset-light model keeps the clinical decision-making cleaner: tests are ordered because they are right for the individual, not because amortization schedules demand it.
Members receive their imaging and diagnostics through verified third-party partners in their local area rather than through a standardized Radence facility. The tradeoffs are potentially having to go to multiple sites to get comprehensive testing, a higher cost point to cover third-party pricing margins and consistency of experience. For a company emphasizing precision and protocol integrity, managing the quality of distributed partners is a non-trivial operational challenge.
What You Actually Get
Radence’s approach is structured around four disease domains: cardiovascular and neurovascular health, cancer risk and detection, neurological and cognitive health, and metabolic and hormonal health. Within those domains, the company’s protocols draw on five categories of data:
Genomic risk mapping. Whole genome sequencing (WGS) to identify inherited predispositions before they become clinical realities. This forms the longitudinal foundation of each member’s risk profile — the baseline against which everything else is interpreted.
Advanced blood biomarkers. Proteomic and metabolomic panels that go substantially beyond a standard lipid panel or comprehensive metabolic panel (CMP). These track biological state and flag early signals of metabolic, inflammatory, or endocrine dysfunction.
Imaging. Organ-specific MRIs, advanced cardiac imaging, and multi-cancer screening. Radence develops proprietary protocols for how these are conducted and interpreted — the objective isn’t to run a standard radiological read but to extract more actionable signal from each scan.
Wearables and continuous monitoring. Functional metrics tracked over time to understand how the above data manifests in real-life physiology.
Microbiome analysis. Gut health profiling that informs systemic risk and is integrated into the broader clinical picture.
The results don’t sit in a portal waiting to be clicked on. Radence’s team of physicians and researchers actively analyzes the full data set and works with each member’s existing primary care physician (PCP) and specialist network to develop dynamic, evolving health plans. This collaborative model is a core design principle: Radence explicitly does not want to replace your doctor. It wants to hand your doctor better intelligence.
The Pricing: Bring Receipts
Let’s be direct. Radence membership requires an annual fee of $50,000 per member, plus a one-time $50,000 enrollment fee per family. There is no insurance reimbursement pathway being promoted. This puts Radence at more than double the price of Fountain Life’s premium APEX program ($21,500/yr) and an order of magnitude above Function Health’s lab-plus-imaging model.
For context: at $50,000 per year, you could instead purchase a Fountain Life APEX membership ($21,500), a Human Longevity Executive Health assessment ($8,000), a Prenuvo whole-body magnetic resonance imaging (MRI) scan, an InsideTracker Ultimate plan, a continuous glucose monitor (CGM) subscription, and still have money left over for a very nice dinner. The question of whether Radence’s integration, interpretation, and curatorial intelligence justifies the premium is legitimate and, as of this writing, largely unanswerable by the published evidence.
Radence leadership justifies the high cost as a necessary condition for launching the startup, drawing parallels to how novel therapeutics enter the market at premium prices to recoup research and development investment, with the stated goal of price reduction as the platform scales. They are also exploring institutional pathways — labor unions, federal employee benefit programs, academic research partnerships — that could eventually broaden access.
The company is also selective by design. As of late 2025, Radence was serving approximately three dozen members, with leadership emphasizing purposeful and selective enrollment focused on individuals where the platform can deliver meaningful impact.
The Scientific Credibility Case
Here is where Radence earns genuine differentiation from the average longevity clinic that has read Outlive and bought a cold plunge. The RA Capital ecosystem brings something most competitors can’t approximate: a formalized process for evaluating whether a diagnostic or therapeutic technology has real clinical validity.
Radence draws on the research and predictive power of RA Capital’s TechAtlas division, which functions as a world-class think tank continuously analyzing scientific and clinical data from around the world. The team that vets Radence’s protocols is the same team that evaluates biopharma investments — people whose livelihoods depend on correctly distinguishing signal from noise in clinical research. That is a materially different epistemic environment than most wellness companies operate in.
Chief Medical Officer Dr. Julie Chen has been explicit about the company’s posture toward the noise problem in precision medicine. As she told Fierce Healthcare, most primary care physicians — including concierge physicians — lack the time and specialized expertise to distinguish genuine clinical advances from premature or overhyped technologies. Radence’s goal is to compress the timeline between the emergence of cutting-edge diagnostics and their responsible clinical deployment.
Despite being only months into its membership launch, Radence has secured a partnership with Mount Sinai, one of the country’s premier academic medical centers — an early institutional validation that lends credibility to its scientific approach.
The Honest Skeptics’ Corner
Keep.Health is constitutionally obligated to note the things Radence can’t yet answer, because nobody has.
The outcomes evidence doesn’t exist yet. Radence is a months-old company with a few dozen members. The claim that catching cancer early through whole genome sequencing and organ-specific MRIs saves lives — while strongly supported in the theoretical literature — has not been validated in Radence members specifically. The protocols are evidence-adjacent, not evidence-confirmed at the population level. The company knows this and says it is investing in outcomes research and clinical validation. We’ll want to see it.
False positives are a real cost. Any program that dramatically expands screening volume will find more incidentalomas — ambiguous findings of uncertain clinical significance that lead to anxiety, follow-on testing, unnecessary procedures, and occasionally real harm. Radence’s team is thoughtful about this; their “right test, right person, right time” framing is explicitly designed to avoid the biomarker-collection-as-sport trap. But the distributed delivery model means the downstream clinical management of incidentalomas will often land with a member’s local PCP, whose experience with this type of data may vary.
The “early adopters pave the way” argument is a classic. When Dr. Chen argues that the affluent early adopters of Radence will eventually democratize access to precision medicine — just as early genome sequencing prices gave way to consumer-accessible direct-to-consumer (DTC) tests — she is making a historically defensible but not guaranteed claim. Many premium healthcare services have remained premium indefinitely. The longevity-for-the-wealthy-first model should be accepted with clear eyes rather than treated as a moral free pass.
No published protocols. The proprietary protocols that differentiate Radence’s imaging reads and genomic panels from standard clinical practice are, well, proprietary. That’s a business reality, not a scandal, but scientific credibility ultimately rests on peer-reviewed transparency that does not yet exist.
How It Compares
| Radence | Fountain Life | Human Longevity | Function Health + Ezra | |
|---|---|---|---|---|
| Annual cost | $50,000/yr + $50K enrollment | $10,500–$21,500/yr | $8,000–$19,000/yr | $365/yr + $899/scan |
| Model | Distributed, asset-light | Proprietary clinics | Proprietary clinics | Distributed |
| Genomics | WGS, full genome | Yes | Yes | No |
| Imaging | Organ-specific MRIs via partners | Full-body MRI in-house | Full-body MRI in-house | Full-body MRI via Ezra |
| Biomarkers | Proteomics, metabolomics | Advanced panels | Advanced panels | 160+ labs |
| Ongoing management | Yes, collaborative with PCP | Yes | Limited | No |
| Scientific backing | RA Capital / TechAtlas | Diamandis/Robbins | J. Craig Venter | Function/Ezra teams |
Who Is This For?
The honest answer is: executives and high-net-worth individuals who are serious about their health, have a family history of cancer or cardiovascular disease, and want something more rigorous than a concierge PCP but less experiential than a $25,000 annual retreat. This is not a wellness purchase. It is a clinical intelligence purchase.
It is also, at this early stage, a vote of confidence in the people running the company more than in the platform’s demonstrated outcomes. If you trust the RA Capital scientific apparatus, and you believe that the compression of clinical intelligence — from genome to imaging to biomarker to functional — will catch things that would otherwise kill you, Radence is the most serious attempt to deliver that at the current frontier.
For everyone else, the Function Health + Ezra combination at approximately $1,300/year, supplemented by an InsideTracker or similar biomarker platform and a good concierge PCP, may deliver 70–80% of the actionable benefit at 2–3% of the cost.
The Bottom Line
Radence is the most intellectually serious entrant in the ultra-premium preventive medicine space in years. The asset-light model is coherent. The scientific backing is genuinely distinguished. The focus on collaborative integration with existing physicians rather than replacement of them is the right clinical philosophy.
What it is not — yet — is proven. A company with a few dozen members and a months-old track record is a compelling hypothesis, not a validated intervention. The price reflects the aspiration and the overhead, not (yet) a body of outcomes data. Watch this space, particularly over the next two to three years as Radence’s member cohort grows and outcomes research begins to surface.
If you have the means and the inclination, Radence may be the most sophisticated bet you can make on your own longevity. Just understand that you are, in a very real sense, an early-stage clinical participant — and price that into your decision accordingly.
For related reading, see our reviews of Fountain Life, Human Longevity, and Function Health / Ezra, as well as our overview of Setting Your Health Baseline.
